The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | What is the current role of radiation therapy in patients with advanced-stage Hodgkin lymphoma?
In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the current role of radiation therapy in patients with advanced-stage Hodgkin lymphoma (HL), noting that it is modest in the era of novel therapeutic regimens. However, Dr Ansell suggests that it may still be considered as consolidation therapy in clinical cases with residual PET positivity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s a very good question as to where does radiation fit in in advanced-stage patients. I do think with the very high response rates, I do think as we’re actually learning more and more about how to really recognize true CRs, even in the face of these new and novel therapies, the role for radiation is very modest. I do think there’s still some evidence to say that if you have residual PET positivity, those patients could be further consolidated with the use of radiation treatment...
That’s a very good question as to where does radiation fit in in advanced-stage patients. I do think with the very high response rates, I do think as we’re actually learning more and more about how to really recognize true CRs, even in the face of these new and novel therapies, the role for radiation is very modest. I do think there’s still some evidence to say that if you have residual PET positivity, those patients could be further consolidated with the use of radiation treatment. I would, however, say that in our practice, we more typically will re-biopsy patients because what we’re concerned about is residual disease that is remaining, and we don’t want to undertreat people when they still have a curative potential. All told though that I think with the use of brentuximab in the BrECADD regimen or nivolumab in the Nivo-AVD combination, the number of advanced stage patients getting radiation is very small.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
